TLIS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLIS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Talis Biomedical's Gross Profit for the three months ended in Jun. 2024 was $0.00 Mil. Talis Biomedical's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Talis Biomedical's Gross Margin % for the quarter that ended in Jun. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Talis Biomedical's Gross Margin % or its related term are showing as below:
During the past 6 years, the highest Gross Margin % of Talis Biomedical was 93.33%. The lowest was -129.76%. And the median was -19.86%.
Talis Biomedical had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Talis Biomedical was 0.00% per year.
The historical data trend for Talis Biomedical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Talis Biomedical Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Gross Margin % | Get a 7-Day Free Trial | - | - | - | -129.76 | 90.05 |
Talis Biomedical Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Gross Margin % | Get a 7-Day Free Trial | 85.42 | 92.11 | 94.70 | 91.78 | - |
For the Medical Devices subindustry, Talis Biomedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Talis Biomedical's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Talis Biomedical's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as
Gross Margin % (A: Dec. 2023 ) | = | Gross Profit (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | 0.4 | / | 0.412 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (0.412 - 0.041) | / | 0.412 | |
= | 90.05 % |
Talis Biomedical's Gross Margin for the quarter that ended in Jun. 2024 is calculated as
Gross Margin % (Q: Jun. 2024 ) | = | Gross Profit (Q: Jun. 2024 ) | / | Revenue (Q: Jun. 2024 ) |
= | 0 | / | 0 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (0 - 0) | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Talis Biomedical (OTCPK:TLIS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Talis Biomedical had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Talis Biomedical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew A Lukowiak | officer: President, other: Chief Scientific Officer | 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078 |
Heinrich Dreismann | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Rebecca Markovich | officer: Interim CFO | CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606 |
Raymond Cheong | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Felix Baker | director, 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director, 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Brian J Blaser | director, officer: President and CEO | 561 CIRCLE LANE, LAKE FOREST IL 60045 |
Ramesh Ramakrishnan | officer: Sr. Vice President, R&D | 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Randal W Scott | director | 171 MAIN STREET #225, LOS ALTOS CA 94022 |
Jeryl L Hilleman | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Kimberly J Popovits | director | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Moody John Roger Jr | officer: Chief Financial Officer | 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062 |
From GuruFocus
By Marketwired • 08-03-2023
By GuruFocus Research • 02-09-2024
By sperokesalga sperokesalga • 05-04-2023
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus News • 10-11-2024
By GuruFocusNews GuruFocusNews • 05-20-2022
By sperokesalga sperokesalga • 05-23-2023
By Business Wire • 06-22-2023
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.